NYSE$CNMD
Conmed Corp. · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Conmed reported a 5.8% increase in sales and a 26.4% increase in adjusted diluted EPS for the fourth quarter of 2024.
CONMED Corporation announced solid sales and earnings growth for the fourth quarter and full-year 2024, with Q4 sales increasing 5.8% to $345.9 million and adjusted diluted EPS rising 26.4% to $1.34, despite persistent supply challenges.
- Sales for Q4 2024 increased by 5.8% year-over-year to $345.9 million, or 6.0% in constant currency.
- Diluted net earnings per share (GAAP) for Q4 2024 were $1.08, up from $1.05 in Q4 2023.
- Adjusted diluted net earnings per share for Q4 2024 increased by 26.4% to $1.34.
- Domestic revenue grew by 6.8% year-over-year, while international revenue increased by 4.4% (5.0% in constant currency).
Headline financials
Revenue & EPS history
Conmed · Revenue · Quarterly
$346M
Revenue by segment
Conmed · $277M total across 2 segments · Q2 2022
- General Surgery$157M—56.6%
- Orthopedic Surgery$120M—43.4%
Forward guidance
CONMED expects full-year 2025 reported revenue to be between $1.344 billion and $1.372 billion, representing 4% to 6% constant currency growth, and adjusted diluted net earnings per share in the range of $4.25 to $4.40.
Tailwinds
- Expected full-year 2025 revenue growth of approximately 4% to 6% in constant currency.
- Anticipated full-year 2025 adjusted diluted net earnings per share in the range of $4.25 to $4.40.
- Management is focused on improving operations and strengthening the foundation for future above-market revenue and profitability growth.
- The company aims for continued solid sales and earnings growth.
- The outlook suggests continued profitability.
Headwinds
- Expected currency headwind of approximately 100 to 120 basis points on revenue growth.
- Anticipated currency headwind of approximately $0.15 to $0.20 on adjusted diluted net earnings per share.
- Guidance excludes any potential impact from recently announced tariffs, which could be a future negative.
- The company navigated persistent supply challenges in 2024, which may continue.
- The company is unable to provide a quantitative reconciliation for forward-looking adjusted diluted net earnings per share due to uncertainty and unreasonable effort regarding acquisition, integration, and other charges.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.0%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+3.0%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+16.5%
Q1 2025
Best reaction
-18.5%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | +1.9% | -0.8% | |
| Q4 2025 | -4.0% | +0.3% | +18.9% | |
| Q3 2025 | -0.1% | +0.6% | -9.8% | |
| Q1 2025 | +16.5% | +13.8% | +15.6% | |
| Q4 2024 | -9.0% | -12.1% | -15.2% | |
| Q3 2024 | +5.5% | +9.0% | +14.5% | |
| Q2 2024 | -6.0% | -5.6% | +5.3% | |
| Q1 2024 | -13.2% | -5.7% | +3.9% | |
| Q4 2023 | -11.7% | -13.0% | -15.7% | |
| Q3 2023 | -0.3% | +3.1% | +15.0% | |
| Q2 2023 | -1.6% | +0.8% | -10.1% | |
| Q1 2023 | +11.2% | +9.2% | +2.7% | |
| Q4 2022 | +3.3% | +6.4% | +0.4% | |
| Q3 2022 | -3.3% | -1.0% | +3.2% | |
| Q2 2022 | -2.5% | -4.5% | -10.0% | |
| Q1 2022 | -8.5% | -19.2% | -17.3% | |
| Q4 2021 | +4.9% | +11.0% | +19.6% | |
| Q3 2021 | +1.5% | +2.0% | -5.9% | |
| Q2 2021 | +1.3% | -0.2% | -1.4% | |
| Q1 2021 | +4.8% | +7.0% | +1.5% | |
| Q4 2020 | -4.6% | -6.1% | +3.1% | |
| Q3 2020 | +2.8% | -3.9% | +29.6% | |
| Q2 2020 | +5.5% | -0.4% | +4.8% | |
| Q1 2020 | +9.2% | +0.5% | +8.5% | |
| Q4 2019 | -2.6% | -4.7% | -11.9% | |
| Q3 2019 | +10.4% | +12.9% | +13.7% | |
| Q2 2019 | +7.3% | +4.5% | +15.3% | |
| Q1 2019 | +0.7% | -2.6% | +0.8% | |
| Q4 2018 | +6.1% | +4.9% | +12.8% | |
| Q3 2018 | -0.6% | +1.3% | +0.8% | |
| Q2 2018 | +8.6% | +5.5% | +8.7% | |
| Q1 2018 | +7.2% | +5.3% | +10.7% | |
| Q4 2017 | +10.2% | +7.1% | +6.3% | |
| Q3 2017 | +1.9% | -2.7% | +0.7% | |
| Q2 2017 | -1.3% | +1.3% | -4.1% | |
| Q1 2017 | +4.2% | +6.9% | +7.6% | |
| Q4 2016 | -6.9% | -4.0% | -6.8% | |
| Q3 2016 | +5.0% | +3.3% | +18.3% | |
| Q2 2016 | -17.5% | -16.9% | -17.0% | |
| Q1 2016 | -4.1% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | -18.5% | — | — | |
| Q2 2015 | -4.3% | — | — | |
| Q1 2015 | +10.7% | — | — | |
| Q4 2014 | -1.4% | — | — | |
| Q3 2014 | +4.4% | — | — | |
| Q2 2014 | -9.5% | — | — | |
| Q1 2014 | -2.8% | — | — | |
| Q4 2013 | +4.2% | — | — | |
| Q3 2013 | -2.7% | — | — | |
| Q2 2013 | +2.8% | — | — | |
| Q1 2013 | -2.7% | — | — | |
| Q4 2012 | +4.6% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | -0.4% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q1 2010 | -0.2% | — | — | |
| Q4 2009 | -0.2% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q3 2010 | -1.8% | — | — | |
| Q3 2011 | -1.8% | — | — | |
| Q2 2011 | -2.3% | — | — | |
| Q4 2010 | -2.3% | — | — | |
| Q2 2010 | -2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro